resTORbio (TORC) News Today → Millionaire Investor makes surprising election prediction (From InvestorPlace) (Ad) Free TORC Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative January 30, 2024 | investing.comAdicet Bio Inc (ACET)February 24, 2023 | finance.yahoo.comMichelle Chaka Joins Torc as Senior Vice President, Safety and RegulatoryJanuary 10, 2023 | finance.yahoo.comTinOne Resources Inc. (TORC.V)September 19, 2022 | forbes.comCelebrity Strategy Consultant Predicts What Will Be The Most Impactful Area In The Pharmaceutical Industry - ForbesSeptember 12, 2022 | bizjournals.comFast-growing cancer cell therapy developer Adicet Bio takes more space - San Francisco Business Times - The Business JournalsJuly 8, 2022 | streetinsider.comForm DEF 14A BiomX Inc. For: Aug 24 - StreetInsider.comJune 21, 2022 | gurufocus.comTerns Pharmaceuticals Appoints Kerry Russell as Chief Medical Officer - GuruFocus.comJune 1, 2022 | streetinsider.comTerns Pharmaceuticals Inc. (TERN) Appoints Kerry Russell as Chief Medical Officer - StreetInsider.comJune 1, 2022 | streetinsider.comTerns Pharmaceuticals Appoints Kerry Russell as Chief Medical Officer - StreetInsider.comJune 1, 2022 | globenewswire.comTerns Pharmaceuticals Appoints Kerry Russell as Chief Medical Officer - GlobeNewswireApril 27, 2022 | streetinsider.comPureTech Announces Annual Results for Year Ended December 31, 2021 - StreetInsider.comApril 26, 2022 | businesswire.comPureTech Announces Annual Results for Year Ended December 31, 2021 - Business WireMarch 21, 2022 | businesswire.com$3.68 Billion Worldwide Cellular Immunotherapy Industry to 2031 - Identify Growth Segments for Investment - ResearchAndMarkets.com - Business WireMarch 15, 2022 | marketscreener.comADICET BIO, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K) - Marketscreener.comFebruary 8, 2022 | seekingalpha.comAdicet Bio: Gamma Delta 1 CAR-T Technology And A Takeover Candidate - Seeking AlphaJanuary 3, 2022 | forbes.comCan The Pharmaceutical Companies Use Basic Aging Biology To Develop Drugs For Age-Related Diseases? - ForbesDecember 9, 2021 | bizjournals.comAdicet soars on early clinical data for cancer cell therapy - San Francisco Business Times - San Francisco Business TimesNovember 11, 2021 | marketscreener.comADICET BIO, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) - marketscreener.comOctober 30, 2021 | marketscreener.comADICET BIO, INC. : Termination of a Material Definitive Agreement (form 8-K) - marketscreener.comOctober 20, 2021 | nasdaq.comNasdaq’s ConnectIR Surpasses 10,000 Bookings as Activity Surges Amid Pandemic - NasdaqAugust 12, 2021 | prnewswire.comGlobal Cellular Immunotherapy Market research Report 2021: Companies are Focusing on Developing Off-the-Shelf Allogeneic Therapies for New and Improved Cancer Treatment - PRNewswireAugust 3, 2021 | streetinsider.comOyster Point Pharma Announces New Chairperson Appointment to Board of Directors - StreetInsider.comAugust 3, 2021 | streetinsider.comOyster Point Pharma Inc. (OYST) Appoints Donald Santel to its Board - StreetInsider.comAugust 2, 2021 | finance.yahoo.comOyster Point Pharma Announces New Chairperson Appointment to Board of Directors - Yahoo Finance Get resTORbio News Delivered to You Automatically Sign up to receive the latest news and ratings for TORC and its competitors with MarketBeat's FREE daily newsletter. Email Address I’m afraid WWIII is a very real possibility (Ad)As one top U.S. cyber official claims: This [tech] is “the most powerful weapon of our time.” That's also why I've produced this new film. Take a look. TORC Media Mentions By Week TORC Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TORC News Sentiment▼0.000.50▲Average Medical News Sentiment TORC News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TORC Articles This Week▼00▲TORC Articles Average Week Get resTORbio News Delivered to You Automatically Sign up to receive the latest news and ratings for TORC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Kronos Bio News Equillium News Aileron Therapeutics News Carisma Therapeutics News Eagle Pharmaceuticals News Mural Oncology News Kezar Life Sciences News MediciNova News Checkpoint Therapeutics News AEON Biopharma News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TORC) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersObama’s Forever Term [exposed]Porter & CompanyCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 Media4 Cryptos BETTER than BitcoinTrue Market InsidersMissed NVDA? Buy this AI stock NOWChaikin AnalyticsUrgent Nvidia WarningAltimetryMost important medical advance in 100 yearsThe Oxford ClubNext President (Not Trump. Not Biden.)The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding resTORbio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
